Mean change in cognitive measures at 12 and 24 weeks follow-up
Test | Assessment | Experimental group | IPP control group | ChEI control group |
---|---|---|---|---|
ADAS-Cog, Alzheimer’s Disease Assessment Scale-Cognitive; BNT, Boston Naming Test; ChEI, cholinesterase inhibitor; IPP, integrated psychostimulation program; MMSE, Mini-Mental State Examination; RBMT, Rivermead Behavioral Memory Test; SKT, Syndrom Kurztest; 0, baseline. | ||||
*Lower scores indicate cognitive improvement. | ||||
MMSE | Baseline | 0 | 0 | 0 |
Week 12 | 1.93 | 0.50 | −1.08 | |
Week 24 | 1.47 | 0.13 | −1.50 | |
ADAS-Cog* | Baseline | 0 | 0 | 0 |
Week 12 | −2.54 | −2.44 | 1.08 | |
Week 24 | −1.07 | 1.12 | 1.83 | |
SKT* | Baseline | 0 | 0 | 0 |
Week 12 | 0.20 | −1.74 | 0.75 | |
Week 24 | 0.27 | −0.81 | 1.33 | |
BNT | Baseline | 0 | 0 | — |
Week 12 | 0.54 | 2.32 | — | |
Week 24 | 0.67 | 0.94 | — | |
Semantic fluency | Baseline | 0 | 0 | — |
Week 12 | 0.26 | 0.82 | — | |
Week 24 | −1.07 | 0.44 | — | |
Phonetic fluency | Baseline | 0 | 0 | — |
Week 12 | 0.53 | −0.25 | — | |
Week 24 | 0.33 | 0 | — | |
Story recall subtest (RBMT) | Baseline | 0 | 0 | — |
Week 12 | 0.47 | 0.12 | — | |
Week 24 | 0.40 | 0.12 | — |